BMS-564,929

BMS-564,929

BMS-564,929 is an androgen/anabolic steroid (AAS) which was developed by Bristol-Myers Squibb for the treatment of hypogonadism and muscle wasting conditions. It is a selective androgen receptor modulator (SARM), a class of drugs that have similar effects to AAS but with reduced androgenic side effects.

History

BMS-564,929 was first synthesized and studied by Bristol-Myers Squibb in the early 2000s. The aim was to develop a drug that could provide the benefits of AAS, such as increased muscle mass and strength, without the associated side effects such as prostate enlargement and cardiovascular disease.

Pharmacology

BMS-564,929 acts as a selective androgen receptor modulator. It binds to the androgen receptor (AR) with high affinity and selectivity, and activates the receptor in a tissue-selective manner. This means it can stimulate muscle growth and strength without causing unwanted side effects in other tissues.

Clinical trials

Several clinical trials have been conducted to assess the safety and efficacy of BMS-564,929. These trials have shown that the drug is well-tolerated and can increase muscle mass and strength in men with hypogonadism or muscle wasting conditions. However, further research is needed to fully understand the long-term effects and potential uses of this drug.

Potential uses

BMS-564,929 has potential uses in the treatment of conditions such as hypogonadism, muscle wasting associated with cancer, HIV/AIDS, and aging, and potentially in the treatment of osteoporosis. However, more research is needed to confirm these potential uses and to determine the optimal dosing and administration protocols.

See also

• Selective androgen receptor modulator
• Androgen receptor
• Bristol-Myers Squibb

This article is a stub related to pharmacology. You can help WikiMD by expanding it!